General
Preferred name
SELUMETINIB
Synonyms
AZD-6244 HYD-SULFATE, ARRY-886, ARRY-142886, AZD-6244 Hydrogen sulfate, AZD-6244, Selumetinib Sulfate ()
AZD6244 ()
Array142886 ()
AZD6244 sulfate ()
ARRY-142886 sulfate ()
AZD6244 (Selumetinib) ()
AZD 6244 ()
Selumetinib (sulfate) ()
ARRY-142886 ()
AZD6244 (sulfate) ()
ARRY-142886 (sulfate) ()
Selumetinib (AZD6244) ()
SELUMETINIB SULFATE ()
ARRY-886 ()
AZD-6244 ()
AZD-6244 HYD-SULFATE ()
AZD6244 HYD-SULFATE ()
AZD6244 HYDROGEN SULFATE ()
AZD-6244 Hydrogen sulfate ()
KOSELUGO ()
Azd6244 hydrogen sulphate ()
Selumetinib hydrogen sulfate ()
Selumetinib sulphate ()
Azd-6244 hydrogen sulphate ()
P&D ID
PD003249
CAS
606143-52-6
865610-79-3
943332-08-9
Tags
available
probe
covalent binder
drug
Approved by
EMA
PMDA
FDA
First approval
2020
Drug indication
Discovery agent
Middle East Respiratory Syndrome (MERS)
Multiple myeloma
Solid tumour/cancer
Non-small-cell lung cancer
Pediatric neurofibromatosis type 1
Thyroid cancer
Melanoma
Severe acute respiratory syndrome (SARS)
pancreatic carcinoma
Drug Status
approved
investigational
Max Phase
4.0
Probe info
Probe type
calculated probe
experimental probe
Probe selectivity
protein-selective
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
21
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
COMMENT
This probe is an allosteric, non-ATP competitive and selective inhibitor of MEK1/2 kinase, a component of RAS-RAF-MEK-ERK growth pathway. It displays a remarkable selectivity for MEK1/2 with IC50 14 nM. It does not inhibit a range of other kinases at 10 uM concentration such as p38 alpha, EGFR, B-RAF, c-SRC and others. The compound does not inhibit phosphorylation of MEK1/2 by RAF yet inhibits phosphorylation of downstream ERK. Cell lines with V600E B-RAF mutation are the most sensitive to this compound. This inhibitor is orally bioavailable and inhibits tumor xenografts in mice at 10-100 mg/kg doses. This inhibitor is highly recommended for cell-based studies in combination with an ATP-competitive MEK inhibitor. The use of this probe to interrogate the role of MEK in vivo is not recommended because there are no data about tissue and organ distribution of the probe upon its administration to animals, and effect on MAPK pathway were not provided. Jun 30 2016 - 12:41am; Selumetinib has anti-proliferative activity in cell line harboring B-RAF and RAS mutations and inhibits MEK1/2 (14 nM). It is relatively selective when tested against a panel of kinases, and commercially available from many sources. Jun 30 2016 - 12:41am
MOA
Covalent;ATP noncompetitive inhibitor
DESCRIPTION
Selumetinib is a selective, orally bioavailable MEK1/2 inhibitor .
(GtoPdb)
PRICE
29
DESCRIPTION
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
DESCRIPTION
Selumetinib (AZD6244) is a MEK1/2 inhibitor that inhibits MEK1 (IC50=14 nM) with potent selectivity and is non-ATP-competitive. Selumetinib has antitumor activity and is used for the treatment of neurofibromatosis type 1 (NF1).
DESCRIPTION
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
PRICE
29
MOA
Covalent Inhibitor
(Chemical Probes.org)
DESCRIPTION
inhibitor of MEK1 and MEK2
(Informer Set)
DESCRIPTION
On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.
(PKIDB)
DESCRIPTION
Potent and selective DPP IV inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Selumetinib sulfate (AZD6244 sulfate) is an orally available, selective and potent MEK1/2 inhibitor that inhibits MEK1/2 phosphorylation and may be useful for the study of symptomatic refractory fibroids in type 1 neurofibromatosis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
417
Organisms
1
Compound Sets
35
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EUbOPEN Chemogenomics Library
Guide to Pharmacology
High-quality chemical probes
Informer Set
JUMP-MOA Compound Set
Kinase Inhibitors (best-in-class)
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tool Compound Set
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
456.0
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
3
cLogP
3.53
TPSA
88.41
Fraction CSP3
0.18
Chiral centers
0.0
Largest ring
6.0
QED
0.39
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
MAP2K1
MAP2K2
MEK1, MEK2
Dual specificity mitogen-activated protein kinase kinase 1
MEK1/2
Apoptosis
Apoptosis related,MEK
Compound status
clinical
Pathway
ERK MAPK signaling
MAPK
MAPK/ERK Pathway
Kinase group
STE
Primary Target
MEK
MOA
ERK
Inhibitor
MEK1 Inhibitors
MEK2 Inhibitors
Inhibitors of Signal Transduction Pathways
MEK inhibitor
Member status
member
Target class
Protein kinase
Kinase
Orthogonal probe
Trametinib
Therapeutic Class
Antiviral Agents
Recommended Cell Concentration
1 uM
Source data
